Announcement

Collapse
No announcement yet.

Vitamins Ward Off Osteoporosis Fractures

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • Vitamins Ward Off Osteoporosis Fractures

    I got this off of Beyonmass and give props to Sachet and Colstone for these posts Vitamins Ward Off Osteoporosis Fractures
    May 13, 2004


    By LINDA A. JOHNSON, Associated Press Writer

    Folate and other B vitamins seem even more of a wonder drug than anyone suspected: Already known to prevent severe birth defects and heart attacks, they may also ward off broken bones from osteoporosis, two major studies suggest.
    The findings underscore doctors' longstanding recommendation that people take multivitamins. They could also further support the government's decision to require bread and cereal makers to fortify their products with folate, also known as folic acid.
    B vitamins are known to reduce levels of homocysteine, an amino acid already linked, at high levels, to an increased risk of heart attacks, strokes and Alzheimer's disease. Now research shows high levels of homocysteine at least double the risk of osteoporosis-related fractures.
    A report from Holland found that the risk of such fractures was twice as high in men and women with homocysteine levels in the top 25 percent, compared with those with lower levels. Similarly, a U.S. study found the risk nearly quadrupled in the top 25 percent of men and nearly doubled in the top 25 percent of women, compared with the 25 percent with the lowest levels.
    "The basic way to keep your homocysteine down in a healthy range is to have plenty of B vitamins," said Dr. Douglas P. Kiel, senior author of the U.S. study and director of medical research at Hebrew Rehabilitation Center for Aged Research and Training Institute in Boston.
    The studies were reported in Thursday's New England Journal of Medicine.
    Kiel said a standard multivitamin, taken once a day, would bring a person's homocysteine levels below the danger point. Foods naturally rich in B vitamins and calcium — including dairy products, broccoli and other green, leafy vegetables, carrots, avocados, cantaloupes, apricots, almonds and peanuts — can also reduce the risk of broken bones.
    Since 1998, when the U.S. government began requiring that folate be added to bread, cereal and other flour products, the resulting drop in Americans' homocysteine levels has been credited with preventing about 48,000 deaths from heart attacks and strokes each year. Also, severe brain and spinal birth defects have dropped 27 percent — the strategy's original purpose.
    Researchers say it is unclear why the same benefit with fractures has not yet been documented. There is also uncertainty as to how homocysteine levels affect bone strength. The prevailing theory is that it interferes with crucial chemical bonds within the bones.
    Experts say it is too soon to recommend routine testing of homocysteine levels, which can cost from $100 to $200. That is partly because the new studies do not actually prove that high homocysteine levels — rather than some other factors — cause weaker bones.
    Kiel's research examined 825 men and 1,174 women, aged 59 to 91, who were part of the Framingham Heart Study, which since 1948 has been studying heart disease risk factors in residents of the Boston suburb. Homocysteine levels in blood samples taken from the patients between 1979 and 1982 were later measured, and the patients were followed for 12 to 15 years to see how many had hip fractures.
    Hip fractures are the leading cause of elderly people being forced into nursing homes; they lead to death within a year for about 20 percent of patients, because of infections and other complications, said Dr. Felicia Cosman, clinical director of the National Osteoporosis Foundation.
    Among the study participants with the highest homocysteine levels, men were about four times more likely to fracture a hip and women about twice as likely, compared with the 25 percent with the lowest levels.
    "This should be another wake-up call to eat better, when you're older, especially," Kiel said.
    Kiel said the highest homocysteine levels would result in about 9 extra hip fractures per 100 men and 9.5 extra fractures per 100 women over 14 years, the average time the patients were studied.
    The report from Erasmus Medical Center in Holland analyzed data from two studies, one in Rotterdam and one in Amsterdam, involving a total of 2,406 people age 55 or older. Those with the highest levels were 1.9 times more likely than the others to suffer osteoporosis-related fractures.
    Research reports since at least 1985 have hinted at a relationship between homocysteine and osteoporosis, said Dr. Todd Stitik, associate professor of physical medicine and rehabilitation at University of Medicine and Dentistry of New Jersey-Newark.
    "This is providing more pieces to that puzzle," he said.
    Stitik said that starting a healthier lifestyle even before middle age can head off problems.
    Besides taking a multivitamin with folate, vitamin B12 and vitamin B6, he recommends plenty of walking or other weight-bearing exercise and eating foods rich in B vitamins.


    __________________
    ~*~*~
    JjCp
    ~*~*~
    Please keep all our people in uniform & their families in your prayers or thoughts.
    ~*~*~
    'The Doctor of the future will give no medicine, but will interest his patients in the care of the human frame, in diet, and in the cause and prevention of disease.'
    ~Thomas Edison
    ~*~*~
    *purrs*



    Report this post to a moderator | IP: Logged

    05-13-2004 10:07 AM



    Coldstone

    tHe BrOkEn OnE

    Registered: Dec 2003
    Status: Offline
    Location: New York City
    Posts: 2306
    Originally posted by Coldstone
    I'll go one step further on this topic and add, a study on a med, that claim to reduce Osteoporosis Fractures, and in some cases actually showed bone regeneration...

    PHILADELPHIA - June 19, 2003 -

    In a long-term clinical trial of Actonel® (risedronate sodium tablets), a low incidence of new vertebral fractures was maintained over 7 years of treatment. The new study, presented today at ENDO 2003, the 85th annual meeting of The Endocrine Society (ENDO), examined the long-term safety profile and sustained efficacy of Actonel in the treatment of postmenopausal osteoporosis.
    "Osteoporosis is treated over a number of years, so long-term protection against fractures is critical," said Jean-Marc Kaufman, M.D., PhD, Unit for Osteoporosis and Metabolic Bone Disease, Ghent University Hospital, Belgium. "This is the longest clinical trial of risedronate to date, and it provides reassurance that the fracture benefits and favorable safety profile of risedronate are sustained over 7 years."

    The study measured fracture incidence in 2 groups of postmenopausal women. One group received Actonel 5 mg daily for 7 years; the other received placebo for 5 years and was then switched to Actonel 5 mg daily for 2 years. For those women treated with Actonel for 7 years, the annualized incidence of new vertebral fractures for years 0-3, 4-5, and 6-7 was 4.7 percent, 5.2 percent, and 3.8 percent, respectively. These data suggest a sustained benefit of Actonel over 7 years of therapy. In the 5-year placebo/2-year Actonel group, the annualized incidence of new vertebral fracture dropped to 3.8 percent during years 6-7 while taking Actonel, down from an incidence of 12.3 percent experienced during years 4-5 on placebo. The incidence of new vertebral fractures in these patients was reduced during years 6 and 7 to a level comparable to those of the treatment group during the 7 years of the study.

    Adverse events in years 6-7, including upper gastrointestinal adverse events, were similar to those in patients taking placebo during the first 5 years of the study.

    Study Details

    This study was the second 2-year extension of an original 3-year placebo-controlled study with Actonel 5mg daily for the treatment of postmenopausal osteoporosis. This open-label extension study evaluated a total of 164 women: 83 patients received Actonel 5 mg daily for 7 years; 81 patients received placebo for 5 years and then were treated with Actonel 5 mg daily for 2 years. The original placebo group was switched to active therapy during years 6 and 7 for ethical reasons. Throughout the 7 years of the study, all patients received 1,000 mg daily calcium and, if baseline levels were low, up to 500 IU Vitamin D daily. The objective of the study was to evaluate the safety and tolerability of 7 years of Actonel treatment.

    About Osteoporosis

    Osteoporosis is a skeletal disorder characterized by reduced bone strength predisposing a person to an increased risk of fracture. According to the National Osteoporosis Foundation, 1.2 million women suffer osteoporotic fractures in the U.S. each year. Risk factors for osteoporosis and subsequent fractures include loss of estrogen production, advanced age, preexisting fractures, and low bone mineral density. Studies show that among postmenopausal women with osteoporosis who experience a spinal fracture, one out of five will suffer their next spinal fracture within just one year, potentially leading to a fracture cascade.

    Preventive measures, such as not smoking, maintaining a balanced diet supplemented with calcium and vitamin D, and engaging in weight-bearing exercise like walking, can reduce an individual's chances of developing osteoporosis. However, in some people these preventive measures may not be enough, and medications like Actonel may be beneficial.

    About Actonel® (risedronate sodium tablets)

    Actonel is developed by Procter & Gamble Pharmaceuticals and co-marketed by Procter & Gamble Pharmaceuticals and Aventis. Actonel 35 mg Once-a-Week and Actonel 5 mg daily are indicated for the prevention and treatment of osteoporosis in postmenopausal women. Actonel 5 mg daily is also indicated for the prevention and treatment of glucocorticoid-induced osteoporosis (GIO) in men and women either initiating or continuing systemic glucocorticoid treatment (≥ 7.5 mg/d prednisone or equivalent) for chronic diseases.

    In clinical trials, Actonel was generally well tolerated. Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min).

    Bisphosphonates may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcer. Patients should pay particular attention to the dosing instructions, as failure to take the drug according to instructions may compromise clinical benefits and may increase the risk of adverse events.

    In clinical trials, the overall incidence of adverse events with Actonel 5 mg daily was comparable to placebo. The most commonly reported adverse events regardless of causality were infection (primarily upper respiratory, placebo 29.7 percent vs. Actonel 5 mg 29.9 percent), back pain (23.6 percent vs. 26.1 percent), and arthralgia (21.1 percent vs. 23.7 percent).

    In a one-year clinical trial comparing Actonel 35 mg Once-a-Week and Actonel 5 mg daily, the overall incidence of adverse events with the two dosing regimens was similar. The most commonly reported adverse events regardless of causality were infection (Actonel 35 mg 20.6 percent vs. Actonel 5 mg 19.0 percent), arthralgia (14.2 percent vs. 11.5 percent) and constipation (12.2 percent vs. 12.5 percent).
    QuickQuote

    I'll go one step further on this topic and add, a study on a med, that claim to reduce Osteoporosis Fractures, and in some cases actually showed bone regeneration...

    PHILADELPHIA - June 19, 2003 -

    In a long-term clinical trial of Actonel® (risedronate sodium tablets), a low incidence of new vertebral fractures was maintained over 7 years of treatment. The new study, presented today at ENDO 2003, the 85th annual meeting of The Endocrine Society (ENDO), examined the long-term safety profile and sustained efficacy of Actonel in the treatment of postmenopausal osteoporosis.
    "Osteoporosis is treated over a number of years, so long-term protection against fractures is critical," said Jean-Marc Kaufman, M.D., PhD, Unit for Osteoporosis and Metabolic Bone Disease, Ghent University Hospital, Belgium. "This is the longest clinical trial of risedronate to date, and it provides reassurance that the fracture benefits and favorable safety profile of risedronate are sustained over 7 years."

    The study measured fracture incidence in 2 groups of postmenopausal women. One group received Actonel 5 mg daily for 7 years; the other received placebo for 5 years and was then switched to Actonel 5 mg daily for 2 years. For those women treated with Actonel for 7 years, the annualized incidence of new vertebral fractures for years 0-3, 4-5, and 6-7 was 4.7 percent, 5.2 percent, and 3.8 percent, respectively. These data suggest a sustained benefit of Actonel over 7 years of therapy. In the 5-year placebo/2-year Actonel group, the annualized incidence of new vertebral fracture dropped to 3.8 percent during years 6-7 while taking Actonel, down from an incidence of 12.3 percent experienced during years 4-5 on placebo. The incidence of new vertebral fractures in these patients was reduced during years 6 and 7 to a level comparable to those of the treatment group during the 7 years of the study.

    Adverse events in years 6-7, including upper gastrointestinal adverse events, were similar to those in patients taking placebo during the first 5 years of the study.

    Study Details

    This study was the second 2-year extension of an original 3-year placebo-controlled study with Actonel 5mg daily for the treatment of postmenopausal osteoporosis. This open-label extension study evaluated a total of 164 women: 83 patients received Actonel 5 mg daily for 7 years; 81 patients received placebo for 5 years and then were treated with Actonel 5 mg daily for 2 years. The original placebo group was switched to active therapy during years 6 and 7 for ethical reasons. Throughout the 7 years of the study, all patients received 1,000 mg daily calcium and, if baseline levels were low, up to 500 IU Vitamin D daily. The objective of the study was to evaluate the safety and tolerability of 7 years of Actonel treatment.

    About Osteoporosis

    Osteoporosis is a skeletal disorder characterized by reduced bone strength predisposing a person to an increased risk of fracture. According to the National Osteoporosis Foundation, 1.2 million women suffer osteoporotic fractures in the U.S. each year. Risk factors for osteoporosis and subsequent fractures include loss of estrogen production, advanced age, preexisting fractures, and low bone mineral density. Studies show that among postmenopausal women with osteoporosis who experience a spinal fracture, one out of five will suffer their next spinal fracture within just one year, potentially leading to a fracture cascade.

    Preventive measures, such as not smoking, maintaining a balanced diet supplemented with calcium and vitamin D, and engaging in weight-bearing exercise like walking, can reduce an individual's chances of developing osteoporosis. However, in some people these preventive measures may not be enough, and medications like Actonel may be beneficial.

    About Actonel® (risedronate sodium tablets)

    Actonel is developed by Procter & Gamble Pharmaceuticals and co-marketed by Procter & Gamble Pharmaceuticals and Aventis. Actonel 35 mg Once-a-Week and Actonel 5 mg daily are indicated for the prevention and treatment of osteoporosis in postmenopausal women. Actonel 5 mg daily is also indicated for the prevention and treatment of glucocorticoid-induced osteoporosis (GIO) in men and women either initiating or continuing systemic glucocorticoid treatment (≥ 7.5 mg/d prednisone or equivalent) for chronic diseases.

    In clinical trials, Actonel was generally well tolerated. Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min).

    Bisphosphonates may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcer. Patients should pay particular attention to the dosing instructions, as failure to take the drug according to instructions may compromise clinical benefits and may increase the risk of adverse events.

    In clinical trials, the overall incidence of adverse events with Actonel 5 mg daily was comparable to placebo. The most commonly reported adverse events regardless of causality were infection (primarily upper respiratory, placebo 29.7 percent vs. Actonel 5 mg 29.9 percent), back pain (23.6 percent vs. 26.1 percent), and arthralgia (21.1 percent vs. 23.7 percent).

    In a one-year clinical trial comparing Actonel 35 mg Once-a-Week and Actonel 5 mg daily, the overall incidence of adverse events with the two dosing regimens was similar. The most commonly reported adverse events regardless of causality were infection (Actonel 35 mg 20.6 percent vs. Actonel 5 mg 19.0 percent), arthralgia (14.2 percent vs. 11.5 percent) and constipation (12.2 percent vs. 12.5 percent).


    __________________
    When I die, bury me upside down, so that the whole world can kiss my ASS!

    Order of the Olive Essence
    Admin@ http://www.proactivehealthnet.com

    " We know that to err is human, but the HIV/AIDS hypothesis is one hell of a mistake"
    Dr. Kary Mullis, Nobel Prize Winner in Chemistry for inventing the Polymerase Chain Reaction


    "The fact is that you can not start off with bad science and end up with good medicine"

Working...
X